CATX Company Profile and Key Details

CATX has shown mixed momentum, gaining 0.83% over the past week and -45.88% over the past quarter, though year-to-date performance is down -11.64%. Short-term trend indicators are mixed aligned (SMA20 -9.8%, SMA50 -1.75%, SMA200 -19.96%). The stock’s 14-day RSI is 43.65 (neutral), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -54.9% below its high and over 51.88% above its low. Average 10-day trading volume of 1.60 million shares is in line with the 3-month average of 1.55 million, indicating normal recent market interest.

Perspective Therapeutics, Inc. has 74.26 million shares outstanding. The public float is 58.98 million shares, elevated short interest at 11.98% of float. This equals 6.29 million shares. The short ratio is 8.24 days. Institutional investors hold 72.34% of the float. Insiders own 18.82%. Lantheus Alpha Therapy, LLC holds 116.77 million shares, Morich Frank has 1.81 million shares and Streeter Jennifer has 1.72 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Perspective Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.89. This means the shares are trading above this model’s fair value.

Perspective Therapeutics, Inc. (AMEX:CATX) closed at $2.54 USD, gaining $0.12 (4.95%) from the previous close of $2.42. The stock is currently mid-range between its 52-week high and low $1.60 and $5.39. With a market capitalization of about $189.19 million, Perspective Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 1.59 million shares, volume is running light vs its 52-week average. Headquartered in Seattle, WA, Perspective Therapeutics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Johan Spoor, the company employs approximately 138 people and listed since November 10, 2005. Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.

Perspective Therapeutics, Inc. generated EPS of -$1.46 over the past year. Five-year average earnings growth is -9.86%. Wall Street analysts project EPS growth of -1.33% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $10.00. The high target offers 640.74% upside. The low target suggests 311.52% downside. The mean target is $12.39. This offers 409.88% upside. Perspective Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 6.06%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -19.05% in August 12, 2024.

Our AI price prediction model suggests that Perspective Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.82%, with price expected at $2.24 by February 03, 2026, within a range of $2.09 to $2.39 3-Month Outlook: Projected rise of 68.72%, reaching $4.10 by April 16, 2026, with a range of $3.71 to $4.44. 1-Year Outlook: Projected gain of 135.39%, with price at $5.72 by January 15, 2027, within a range of $0.00 to $9.51.

Perspective Therapeutics, Inc. (AMEX:CATX) shares are down -11.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Perspective Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.71. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.00, suggesting 517.28% upside. Our AI forecast model points to short-term weakness (-7.82% over two weeks), a medium-term rise (68.72% over three months), and a longer-term gain (135.39% over one year), with expected trading ranges indicating moderate volatility.

Perspective Therapeutics, Inc. trades at a P/E ratio of -1.71, slightly below the S&P 500 average, with a price-to-sales ratio of 215.24 and a price-to-book ratio of 0.75 suggesting the stock is closer to book value. The P/FCF stands at -1.73, also below market averages.